First-of-its-Kind Docuseries Uncovers Patients’ ‘Stories of Resilience’ Merck known as MSD outside the United States and Canada, in collaboration with the breast cancer advocacy community and Emmy-nominated actress, Yvonne Orji, launched a new initiative, Uncovering TNBC to shed light on the unique challenges Black women face when diagnosed with triple-negative breast cancer . Non-Hispanic Black women are ...

First-of-its-Kind Docuseries Uncovers Patients' ‘Stories of Resilience'

Merck (NYSE: MRK), known as MSD outside the United States and Canada, in collaboration with the breast cancer advocacy community and Emmy-nominated actress, Yvonne Orji, launched a new initiative, Uncovering TNBC , to shed light on the unique challenges Black women face when diagnosed with triple-negative breast cancer (TNBC). Non-Hispanic Black women are approximately two times more likely to have TNBC than non-Hispanic white women, and compared to white women, Black women are more likely to die of the disease. Join Yvonne as she speaks with Sharon, Tiah and Damesha, three women diagnosed with TNBC, who share their stories of triumphs while also discussing the health disparities Black women can face. Through the web docuseries and educational materials, Uncovering TNBC aims to inform Black women and empower them to advocate for themselves with their health care team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005206/en/

Emmy-nominated actress, Yvonne Orji. (Photo: Business Wire)

Emmy-nominated actress, Yvonne Orji. (Photo: Business Wire)

With a master's degree in public health and a nurse for a mother, Yvonne has been passionate about closing the health care equity gap since before she became a TV star.

"I know firsthand how important it is for Black women to take charge of their health and advocate for themselves. Data shows women in our community have a higher chance of developing TNBC, but we can take steps to help protect ourselves and our families," said Yvonne. "I hope these stories uplift women with TNBC and inspire them to get the care they need."

The centerpiece of the Uncovering TNBC campaign is a three-episode web docuseries that highlights the challenges Black women with TNBC can face throughout their cancer journeys. Hosted by Yvonne, the docuseries spotlights three brave warriors and their experiences with TNBC: Damesha from North Carolina, Sharon from Virginia and Tiah from Georgia. The series aims to amplify the stories of Black women with TNBC and offers resources that will help others understand their risks and advocate for themselves. The initiative also includes a webpage of educational information for women who have a higher chance of developing or are newly diagnosed with TNBC and their loved ones.

"There is no shortage of breast cancer resources, yet so few are developed with the unique needs of Black women in mind," said Maimah Karmo, founder and CEO, Tigerlily Foundation. "As a native of Liberia myself, I am proud to collaborate with Merck and Ms. Orji to support the tireless efforts to meet that need and further bridge the gap to care."

"We're honored to collaborate with advocacy organizations who have been at the forefront of fighting for heath equity in the breast cancer community on this important campaign," said Jill DeSimone, president, U.S. Oncology, Merck. "For Black women with TNBC, optimal care is about more than just treating cancer: It's about being understood and supported. Uncovering TNBC is an important program that is part of our broader efforts at Merck to help advance health equity for all people with cancer."

About Uncovering TNBC

In collaboration with Susan G. Komen, Living Beyond Breast Cancer, Tigerlily Foundation, and Triple Negative Breast Cancer Foundation, Uncovering TNBC was developed specifically for Black women, who have a higher chance of developing or are newly diagnosed with triple-negative breast cancer (TNBC) . TNBC accounts for about 10-15% of all breast cancers and is an aggressive type of cancer that is often difficult to treat. Black women who have a higher chance of developing or are newly diagnosed with TNBC can face unique disparities, including inadequate breast cancer screening, lack of access to treatment and less access to preventive and educational information.

Uncovering TNBC offers strategies to help address the barriers Black women can face in their journey. Through culturally relevant, educational and solution-oriented content, the program aims to support patients from diagnosis to survivorship. Information and resources can be found on UncoverTNBC.com .

About Yvonne Orji

Yvonne Orji is a Nigerian-American Emmy-nominated actress, comedian and writer who continues to display her versatility and passion with each project she takes on. In addition to her starring role in the critically acclaimed HBO comedy series, Insecure, she is a distinguished stand-up comedian, feature film star, podcast host and published author.

Outside of her creative work, Yvonne is dedicated to her charitable efforts. In 2008, she spent six months working in post-conflict Liberia with Population Services International (PSI), a non-governmental organization (NGO) that uses social marketing to promote health behaviors. While in Liberia, she worked with a group of talented youth to help build a mentoring program and a weekly talk show that helped educate and prevent teen pregnancy and HIV/AIDS.

Yvonne has brought her work with the youth community back to the States, where she is now involved with (RED) campaigns and faith-based youth ministries.

About Merck

For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter , Facebook , Instagram , YouTube and LinkedIn .

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2020 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( www.sec.gov ).

Media Contacts:

Andrea Park
(908) 740-1281

Ayn Wisler
(917) 691-6218

Melissa Moody
(215) 407-3536

News Provided by Business Wire via QuoteMedia

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0% (95% confidence interval [CI]: 0.1, 5.9; nominal p-value=0.0218) and a relative risk reduction of 30% (relative risk 0.70; 95% CI: 0.49, 0.99). Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211126005279/en/

Keep reading... Show less

Jamieson Wellness Inc. Announces Appointment of New Director

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL), announced today the appointment of Tania M. Clarke, Senior Vice-President and Chief Financial Officer of New Look Vision Group Inc., to the Company's Board of Directors.

"I am very pleased to welcome Ms. Clarke to our Board of Directors," said David Williams, Chairman of the Board. "Ms. Clarke's strong financial acumen coupled with her global consumer and retail experience will be invaluable as we continue to expand our reach to consumers around the world. Based in Montreal, Ms. Clarke will also provide more local perspective to support our continued growth in Canada and specifically the Quebec market."

Keep reading... Show less

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.

To view and listen to the webcast, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.

Keep reading... Show less

Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, executive vice president and president of Human Health, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021 at 10:30 a.m. ET.

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at https://investors.merck.com/events-and-presentations/default.aspx .

Keep reading... Show less

Health Canada Approves KEYTRUDA® in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1

Conditional Approval Based on Data from Phase 3 KEYNOTE-355 Trial; Introduces First Breast Cancer Indication for KEYTRUDA ®

Merck (NYSE: MRK), known as MSD outside the United States and Canada today announced that Health Canada has granted conditional approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) and who have not received prior chemotherapy for metastatic disease. 1 This conditional approval is based on the results of the pivotal Phase 3 KEYNOTE-355 trial which demonstrated KEYTRUDA ® 's ability to improve progression-free survival (PFS) in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabinecarboplatin), as compared to chemotherapy alone. 2

Keep reading... Show less
Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University

Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University

Love Pharma Inc. ("LOVE" and or the "Company") (CSE:LUV) (FSE:G1Q0), is pleased to announce that it has executed a Letter of Intent ("LOI") to acquire 100% of MicroDoz Therapy Inc. ("MicroDoz"), which has an exclusive partnership and license with a world leading university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder. Upon the closing of the definitive agreement, the Company expects to release the details of the program and university partner

This new partnership and development program will add to the Company's comprehensive portfolio of intellectual property and further validate the Company's effort to be a frontrunner in the psychedelics and therapeutics space.

Keep reading... Show less

Top News

Related News